National Biodefense Science Board, 28645 [2020-10156]
Download as PDF
<![CDATA[
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 85, No. 93 / Wednesday, May 13, 2020 / Notices
Respondent’s research contribution.
Respondent agreed that she shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI.
Respondent agreed to maintain
responsibility for compliance with the
agreed upon supervision plan.
(2) The requirements for Respondent’s
supervision plan are as follows:
i. A committee of 2–3 senior faculty
members at the institution who are
familiar with Respondent’s field of
research, but not including
Respondent’s supervisor or
collaborators, will provide oversight and
guidance for three (3) years from the
effective date of the Agreement. The
committee will review primary data
from Respondent’s laboratory on a
quarterly basis and submit a report to
ORI at six (6) month intervals, setting
forth the committee meeting dates and
Respondent’s compliance with
appropriate research standards and
confirming the integrity of Respondent’s
research.
ii. The committee will conduct an
advance review of any PHS grant
applications (including supplements,
resubmissions, etc.), manuscripts
reporting PHS-funded research
submitted for publication, and abstracts.
The review will include a discussion
with Respondent of the primary data
represented in those documents and
will include a certification to ORI that
the data presented in the proposed
application/publication is supported by
the research record.
(3) Respondent agreed that for a
period of three (3) years beginning on
March 27, 2020, any institution
employing her shall submit, in
conjunction with each application of
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract.
(4) If no supervisory plan is provided
to ORI, Respondent agreed to provide
certification to ORI at the conclusion of
the supervision period that she has not
engaged in, applied for, or had her name
included on any application, proposal,
or other request for PHS funds without
prior notification to ORI.
(5) Respondent agreed to exclude
herself voluntarily from serving in any
advisory capacity to PHS including, but
not limited to, service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant for
VerDate Sep<11>2014
19:53 May 12, 2020
Jkt 250001
a period of three (3) years, beginning on
March 27, 2020.
(6) As a condition of the Agreement,
Respondent will request that the
following papers be corrected or
retracted in accordance with 42 CFR
93.407(a)(1):
• PLoS One 2013;8(1):e50598
• PLoS One 2013;8(8):e74022
• J Gen Virol. 2014;95(Pt 2):331–6
• J Virol. 2014;88(17):9718–27
• Vaccine 2014;32(35):4428–35
• Virology 2015;484:163–9
• J Gen Virol. 2016;97(6):1297–1303
Respondent will copy ORI and the
Research Integrity Officer at UMD on
the correspondence.
Dated: May 8, 2020.
Elisabeth A. Handley,
Director, Office of Research Integrity, Office
of the Assistant Secretary for Health.
[FR Doc. 2020–10253 Filed 5–12–20; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Biodefense Science Board
Office of the Assistant
Secretary for Preparedness and
Response (ASPR), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The National Biodefense
Science Board (NBSB) is authorized
under Section 319M of the Public PHS
Act, as added by Section 402 of the
Pandemic and All-Hazards
Preparedness Act of 2006 and amended
by Section 404 of the Pandemic and AllHazards Preparedness Reauthorization
Act. The Board is governed by the
Federal Advisory Committee, which sets
forth standards for the formation and
use of advisory committees. The NBSB
provides expert advice and guidance on
scientific, technical, and other matters
of special interest to the Department
regarding current and future chemical,
biological, nuclear, and radiological
agents, whether naturally occurring,
accidental, or deliberate.
Background: The May 13, 2020, NBSB
public teleconference is dedicated to the
discussion of recommendations on two
topics: (1) NBSB Rapid medical
countermeasures (MCM) for Disease X
and (2) Integrating Clinical Disaster
Response Training with Community and
State Based Emergency Planning. We
will post modifications to the agenda
and/or topics on the NBSB meeting
website, which is located at https://
www.phe.gov/nbsb.
Availability of Materials: We will post
all teleconference materials prior to the
SUMMARY:
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
28645
teleconference on May 13, 2020, on the
website located at https://www.phe.gov/
nbsb.
Procedures for Providing Public Input:
Members of the public may attend the
public teleconference via a toll-free callin phone number, which is available on
the NBSB website at https://
www.phe.gov/nbsb.
FOR FURTHER INFORMATION CONTACT:
Maxine Kellman, DVM, Ph.D., PMP,
Alternate Designated Federal Official for
National Advisory Committees,
Washington, DC, Office (202) 260–0447
or email maxine.kellman@hhs.gov.
SUPPLEMENTARY INFORMATION: We
encourage members of the public to
provide written comments that are
relevant to the NBSB public
teleconference prior to May 13, 2020.
Send written comments by email to
nbsb@hhs.gov with ‘‘NBSB Public
Comment’’ in the subject line. The
NBSB Chair will respond to comments
received by May 13, 2020, via email
and/or during the public teleconference.
Due to the Coronavirus Disease 2019
(COVID–19) pandemic response, there
was an administrative delay with the
posting of this Federal Register notice
to announce the National Biodefense
Science Board (NBSB) May 13, 2020
Public Teleconference.
Robert P. Kadlec,
Assistant Secretary for Preparedness and
Response.
[FR Doc. 2020–10156 Filed 5–12–20; 8:45 am]
BILLING CODE 4150–37–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Environmental
Health Sciences; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Environmental Health Sciences Council.
The meeting will be open to the
public as indicated below. Individuals
who plan to attend virtually and will
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
E:\FR\FM\13MYN1.SGM
13MYN1
]]>Agencies
[Federal Register Volume 85, Number 93 (Wednesday, May 13, 2020)]
[Notices]
[Page 28645]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-10156]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Biodefense Science Board
AGENCY: Office of the Assistant Secretary for Preparedness and Response
(ASPR), Department of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Biodefense Science Board (NBSB) is authorized
under Section 319M of the Public PHS Act, as added by Section 402 of
the Pandemic and All-Hazards Preparedness Act of 2006 and amended by
Section 404 of the Pandemic and All-Hazards Preparedness
Reauthorization Act. The Board is governed by the Federal Advisory
Committee, which sets forth standards for the formation and use of
advisory committees. The NBSB provides expert advice and guidance on
scientific, technical, and other matters of special interest to the
Department regarding current and future chemical, biological, nuclear,
and radiological agents, whether naturally occurring, accidental, or
deliberate.
Background: The May 13, 2020, NBSB public teleconference is
dedicated to the discussion of recommendations on two topics: (1) NBSB
Rapid medical countermeasures (MCM) for Disease X and (2) Integrating
Clinical Disaster Response Training with Community and State Based
Emergency Planning. We will post modifications to the agenda and/or
topics on the NBSB meeting website, which is located at https://www.phe.gov/nbsb.
Availability of Materials: We will post all teleconference
materials prior to the teleconference on May 13, 2020, on the website
located at https://www.phe.gov/nbsb.
Procedures for Providing Public Input: Members of the public may
attend the public teleconference via a toll-free call-in phone number,
which is available on the NBSB website at https://www.phe.gov/nbsb.
FOR FURTHER INFORMATION CONTACT: Maxine Kellman, DVM, Ph.D., PMP,
Alternate Designated Federal Official for National Advisory Committees,
Washington, DC, Office (202) 260-0447 or email [email protected].
SUPPLEMENTARY INFORMATION: We encourage members of the public to
provide written comments that are relevant to the NBSB public
teleconference prior to May 13, 2020. Send written comments by email to
[email protected] with ``NBSB Public Comment'' in the subject line. The NBSB
Chair will respond to comments received by May 13, 2020, via email and/
or during the public teleconference. Due to the Coronavirus Disease
2019 (COVID-19) pandemic response, there was an administrative delay
with the posting of this Federal Register notice to announce the
National Biodefense Science Board (NBSB) May 13, 2020 Public
Teleconference.
Robert P. Kadlec,
Assistant Secretary for Preparedness and Response.
[FR Doc. 2020-10156 Filed 5-12-20; 8:45 am]
BILLING CODE 4150-37-P
